Flag of the European Union EU Clinical Trials Register Help

Clinical trials for multiple sclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    631 result(s) found for: multiple sclerosis. Displaying page 21 of 32.
    «« First « Previous 17  18  19  20  21  22  23  24  25  Next» Last»»
    EudraCT Number: 2005-001949-42 Sponsor Protocol Number: BRD50 Start Date*: 2005-09-08
    Sponsor Name:University College London
    Full Title: A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000985-36 Sponsor Protocol Number: EMCAM-2011-001 Start Date*: 2013-02-22
    Sponsor Name:JOSE MANUEL GARCIA DOMINGUEZ
    Full Title: Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as "responders" and "not responders" under t...
    Medical condition: Spasticity due to multiple sclerosis identified as "responders" and "not responders" under treatment with Sativex
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10041416 Spasticity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001973-21 Sponsor Protocol Number: GNC-402 Start Date*: 2021-07-09
    Sponsor Name:GeNeuro Innovation SAS
    Full Title: A long-term extension of Study GNC-401 with temelimab in patients with Relapsing forms of Multiple Sclerosis (RMS) under treatment with rituximab
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004533-32 Sponsor Protocol Number: 109MS305 Start Date*: 2014-04-28
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia Pacific Region and Other Countries With Relapsing-Remitting Multiple Scle...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003919-53 Sponsor Protocol Number: GN41791 Start Date*: 2020-09-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PR...
    Medical condition: Primary Progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005586-39 Sponsor Protocol Number: 101MS409 Start Date*: 2015-01-29
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS)
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000644-55 Sponsor Protocol Number: EFC16034 Start Date*: 2020-12-22
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) LV (Completed) SK (Completed) BE (Completed) NO (Completed) GR (Completed) NL (Completed) PT (Completed) HU (Completed) HR (Completed) IT (Completed) EE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000145-38 Sponsor Protocol Number: C0743T06 Start Date*: 2004-11-16
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2, Double-blind, Placebo-controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-remit...
    Medical condition: Relapse-remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    10048393
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006268-32 Sponsor Protocol Number: MSBOTOX Start Date*: 2008-01-23
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY IN INFLAMMATORY AND DEMIELINIZZATING DISEASE OF CENTRAL NERVOUS SYSTEM.
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003126-83 Sponsor Protocol Number: EMR200559005 Start Date*: 2014-06-23
    Sponsor Name:Merck KGaA
    Full Title: A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) HU (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000048-23 Sponsor Protocol Number: P2-IMU-838-PMS Start Date*: 2021-11-04
    Sponsor Name:Immunic AG
    Full Title: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
    Medical condition: Progressive forms of Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    26.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) BG (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003627-38 Sponsor Protocol Number: H3M116477 Start Date*: 2013-01-30
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) CZ (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004051-11 Sponsor Protocol Number: 1 Start Date*: 2008-12-18
    Sponsor Name:Oxford Racliffe NHS Trust
    Full Title: Amiloride Treatment in Multiple Sclerosis
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013284-19 Sponsor Protocol Number: HINABS-ITI Start Date*: 2009-12-10
    Sponsor Name:Medical University Innsbruck
    Full Title: Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta
    Medical condition: multiple sclerosis patients with neutralizing antibodies against interferon-beta
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004972-20 Sponsor Protocol Number: MS200527ˍ0080 Start Date*: 2020-11-05
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) HU (Prematurely Ended) BE (Completed) CZ (Completed) BG (Completed) ES (Completed) FI (Prematurely Ended) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001896-19 Sponsor Protocol Number: P2-IMU-838-MS Start Date*: 2018-12-17
    Sponsor Name:Immunic AG
    Full Title: Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and t...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) DE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2012-002357-35 Sponsor Protocol Number: CRO1959 Start Date*: 2012-10-23
    Sponsor Name:Imperial College London
    Full Title: Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS)
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004040-30 Sponsor Protocol Number: EOC.NSI.11.01 Start Date*: 2013-05-24
    Sponsor Name:Ospedale Regionale di Lugano
    Full Title: Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study
    Medical condition: relapse-remitting multiple sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003484-30 Sponsor Protocol Number: CFTY720DES03 Start Date*: 2011-10-26
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or...
    Medical condition: Multiple Sclerosis relapsing-remitting course
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002373-95 Sponsor Protocol Number: 270682 Start Date*: 2021-01-07
    Sponsor Name:Haukeland University Hospital
    Full Title: Study of Mesenchymal Autologous stem cells as Regenerative Treatment for Multiple Sclerosis
    Medical condition: Multiple sclerosis (MS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 17  18  19  20  21  22  23  24  25  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 15:23:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA